PuSH - Publikationsserver des Helmholtz Zentrums München

Noseda, A.C.D.* ; Rodrigues, L.S.* ; Targa, A.D.S.* ; Ilkiw, J.L.* ; Fagotti, J.* ; dos Santos, P.D.* ; Cecon, E.* ; Markus, R.P.* ; Solimena, M. ; Jockers, R.* ; Lima, M.M.S.*

MT2 melatonin receptors expressed in the olfactory bulb modulate depressive-like behavior and olfaction in the 6-OHDA model of Parkinson's disease.

Eur. J. Pharmacol. 891:173722 (2021)
DOI Verlagsversion bestellen
Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.
Melatonin MT1 and MT2 receptors are expressed in the glomerular layer of the olfactory bulb (OB); however, the role of these receptors has not been evaluated until now. Considering the association of the OB with olfactory and depressive disorders in Parkinson's disease (PD), we sought to investigate the involvement of melatonin receptors in these non-motor disturbances in an intranigral 6-hydroxydopamine (6-OHDA)-lesioned rat model of PD. We demonstrate the presence of functional melatonin receptors in dopaminergic neurons of the glomerular layer. Local administration of melatonin (MLT, 1 μg/μl), luzindole (LUZ, 5 μg/μl) or the MT2-selective receptor drug 4-P-PDOT (5 μg/μl) reversed the depressive-like behavior elicited by 6-OHDA. Sequential administration of 4-P-PDOT and MLT (5 μg/μl, 1 μg/μl) promoted additive antidepressant-like effects. In the evaluation of olfactory discrimination, LUZ induced an olfactory impairment when associated with the nigral lesion-induced impairment. Thus, our results suggest that melatonin MT2 receptors expressed in the glomerular layer are involved in depressive-like behaviors and in olfactory function associated with PD.
Altmetric
Weitere Metriken?
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter 6-hydroxydopamine ; Depressive Disorder ; Melatonin Receptors ; Olfactory Bulb ; Olfactory Impairment ; Parkinson's Disease; Forced Swim Test; Adult Neurogenesis; Animal-models; Mice; Internalization; Pharmacology; Involvement; Dysfunction; Efficacy; Exposure
ISSN (print) / ISBN 0014-2999
e-ISSN 0014-2999
Quellenangaben Band: 891, Heft: , Seiten: , Artikelnummer: 173722 Supplement: ,
Verlag Elsevier
Verlagsort Radarweg 29, 1043 Nx Amsterdam, Netherlands
Begutachtungsstatus Peer reviewed
Institut(e) Institute for Pancreatic Beta Cell Research (IPI)
Förderungen CNPq fellowships
Institut National de la Sante et de la Recherche Medicale (INSERM), Centre National de la Recherche Scientifique (CNRS)
French National Research Agency (ANR)
Fondation Recherche Medicale
Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq), Brazil
Fundacao Araucaria (Programa de Apoio a Nucleos de Excelencia-PRONEX)
Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)